LUGANO, 26 April 2018 – ESMO, the leading professional organisation for medical oncology, shares concerns expressed in a scientific paper (1) and reflected in the international media about the rising costs of cancer medicines.
The authors of The Journal of Oncology Practice paper (1) used both the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2) and ASCO's Value Framework to assess whether the clinical benefits of novel anticancer drugs have increased over time in parallel with increasing pricing. The authors concluded that while costs of these have risen over the past decade, their clinical benefit has not improved proportionally.
The ESMO-MCBS uses a rational, structured and consistent approach to grade the magnitude of clinical benefit that can be expected from anticancer treatments.
Prof. Elisabeth de Vries, Chair of the ESMO Cancer Medicines Committee and the ESMO-MCBS Working Group, (3) said: "The ESMO-MCBS provides unbiased information to help guide physicians and decision makers to grade drugs newly approved by the European Medicines Agency (EMA) by assessing their clinical benefit. It is an important first step in the major and ongoing task of evaluating value in cancer care which is essential for the appropriate use of limited public funds in delivering cost-effective and more affordable cancer care."
Prof. Josep Tabernero, ESMO President, said: "Access to anticancer medicines is an essential component of high quality cancer care, hence affordability is crucial in providing optimal treatment and patient care." There are however many additional critical factors. "Other major considerations include the availability of highly trained oncologists, up-to-the-minute diagnostics, the necessary funding and frameworks in place for research, a holistic approach to cancer care incorporating supportive and palliative care, and a multidisciplinary approach to best manage and treat our patients," continued Tabernero.
"ESMO calls for a multi-stakeholder commitment towards ultimately ensuring access to optimal cancer care for all patients," said Tabernero. "Sustainable cancer care is a key pillar of the ESMO 2020 Vision (4) and we are determined to continue pursuing this goal in collaboration with our partners."
###
References
1 Saluja R, Arciero VS, Cheng S, McDonald E, Wong WWL, Cheung MC, Chan KKW. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time. J Oncol Pract. 2018 Mar 30:JOP1700058. doi: 10.1200/JOP.17.00058. https://www.ncbi.nlm.nih.gov/pubmed/29601250
2 http://esmo.org/Policy/Magnitude-of-Clinical-Benefit-Scale
3 http://esmo.org/About-Us/Who-We-Are/Guidelines-Committee/Magnitude-of-Clinical-Benefit-Scale-Working-Group
4 http://www.esmo.org/About-Us/ESMO-2020-Vision
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. ESMO is committed to offer the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide. http://www.esmo.org
Twitter: @myESMO
Facebook: esmo.org
Youtube: ESMOchannel
Media Contact
ESMO Press Office
[email protected]
@myesmo
http://www.esmo.org
http://www.esmo.org/Press-Office/Press-Releases/Quality-Cancer-Care-Anticancer-Medicines-Cost-MCBS
